Alpine Immune Sciences, Inc. (ALPN)


+0.02 (+0.24%)
Symbol ALPN
Price $8.3
Beta 1.313
Volume Avg. 0.12M
Market Cap 381.090M
Shares () -
52 Week Range 4.82-10.3
1y Target Est -
DCF Unlevered ALPN DCF ->
DCF Levered ALPN LDCF ->
ROE -41.76% Strong Sell
ROA -18.54% Sell
Operating Margin -
Debt / Equity 60.21% Buy
P/E -
P/B 1.44 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest ALPN news

Dr. Mitchell Gold
NASDAQ Global Market

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.